ArticleNeuroepidemiology2026
Epidemiology and Treatment of Patients with Essential Tremor: A Retrospective Cohort Analysis in the United Kingdom.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEssential tremor (ET) carries a substantial burden and unmet need. Limited real-world evidence exists for the epidemiology, clinical characteristics, and treatment patterns of ET in the UK. We conducted a retrospective cohort study using a large electronic health records database from the UK.
methodsData were obtained from Clinical Practice Research Datalink linked with Hospital Episode Statistics inpatient and outpatient databases from 1 January 2010 to 31 December 2022. Point prevalence and cumulative incidence were assessed, including age- and sex-standardized estimates to the Office for National Statistics mid-year population estimates. In a cohort of newly diagnosed ET patients (1 January 2011-31 March 2020), we evaluated baseline characteristics, clinical features, and treatment patterns. We used descriptive statistics as well as time-to-event analyses (Kaplan-Meier methodology).
resultsAge-sex standardized prevalence ranged from 20.62 to 55.08 per 100,000 persons (2010-2021), peaking at 55.08 in 2019. Age-sex standardized cumulative incidence ranged from 3.85 to 6.81 per 100,000 persons (2011-2021), peaking at 6.81 in 2017. Common comorbidities included hypertension (23.43%), pain disorders (17.12%), and diabetes (15.64%). Most patients (86.07%) received at least one pharmacological therapy: propranolol (68.34%), primidone (27.68%), and gabapentin (22.14%) were most frequently used. Median time from diagnosis to treatment initiation was 0.43 months (95% confidence interval [CI]: 0.36-0.46); median time to discontinuation from start of first therapy was 4.63 months (95% CI: 4.27-5.19); median time to switch was 21.22 months (95% CI: 20.14-22.60).
conclusionThis study provides UK-based evidence on ET epidemiology, clinical features, and treatments. Despite lower epidemiological estimates attributable to the requirement for two confirmed diagnoses - a methodological choice prioritizing diagnostic specificity in a condition that is frequently overdiagnosed - ET burden and unmet needs remain substantial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.